×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:RMTI

Rockwell Medical Stock Forecast, Price & News

$1.49
+0.13 (+9.56%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.29
$1.70
50-Day Range
$1.28
$22.22
52-Week Range
$1.25
$10.78
Volume
199,303 shs
Average Volume
110,428 shs
Market Capitalization
$12.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
30 days | 90 days | 365 days | Advanced Chart

Receive RMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rockwell Medical and its competitors with MarketBeat's FREE daily newsletter.

RMTI Stock Forecast (MarketRank)

Overall MarketRank

1.53 out of 5 stars

Medical Sector

1013th out of 1,418 stocks

Pharmaceutical Preparations Industry

508th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Rockwell Medical logo

About Rockwell Medical (NASDAQ:RMTI)

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

RMTI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:RMTI
CUSIP
77437410
Employees
300
Year Founded
1995

Company Calendar

Last Earnings
5/19/2022
Today
6/24/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$33.00
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+2,114.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-32.67 million
Pretax Margin
-51.27%

Debt

Sales & Book Value

Annual Sales
$61.93 million
Book Value
$0.30 per share

Miscellaneous

Free Float
8,295,000
Market Cap
$12.73 million
Optionable
Optionable
Beta
1.13

Social Links















Rockwell Medical Frequently Asked Questions

Should I buy or sell Rockwell Medical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rockwell Medical stock.
View analyst ratings for Rockwell Medical
or view top-rated stocks.

What is Rockwell Medical's stock price forecast for 2022?

1 brokerages have issued 12-month price objectives for Rockwell Medical's stock. Their RMTI stock forecasts range from $33.00 to $33.00. On average, they anticipate Rockwell Medical's stock price to reach $33.00 in the next year. This suggests a possible upside of 2,114.8% from the stock's current price.
View analysts' price targets for Rockwell Medical
or view top-rated stocks among Wall Street analysts.

How has Rockwell Medical's stock performed in 2022?

Rockwell Medical's stock was trading at $4.51 at the beginning of the year. Since then, RMTI shares have decreased by 67.0% and is now trading at $1.49.
View the best growth stocks for 2022 here
.

Are investors shorting Rockwell Medical?

Rockwell Medical saw a drop in short interest in May. As of May 31st, there was short interest totaling 242,400 shares, a drop of 40.6% from the May 15th total of 408,100 shares. Based on an average daily volume of 62,200 shares, the short-interest ratio is currently 3.9 days. Approximately 3.1% of the shares of the stock are sold short.
View Rockwell Medical's Short Interest
.

When is Rockwell Medical's next earnings date?

Rockwell Medical is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Rockwell Medical
.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings results on Thursday, May, 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.15. The firm had revenue of $16.12 million for the quarter, compared to the consensus estimate of $18.80 million. Rockwell Medical had a negative trailing twelve-month return on equity of 474.88% and a negative net margin of 51.27%. During the same quarter in the previous year, the business earned ($0.08) earnings per share.
View Rockwell Medical's earnings history
.

When did Rockwell Medical's stock split? How did Rockwell Medical's stock split work?

Rockwell Medical's stock reverse split on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of Rockwell Medical stock prior to the reverse split would have 9 shares after the split.

Who are Rockwell Medical's key executives?

Rockwell Medical's management team includes the following people:
  • Dr. Russell H. Ellison M.D., M.Sc., MSc., Pres, CEO & Director (Age 74, Pay $501.13k)
  • Mr. Russell L. Skibsted M.B.A., Exec. VP, CFO & Chief Bus. Officer (Age 63, Pay $598.92k)
  • Mr. Michael DeYoung, VP of Operations
  • Mr. Paul E. McGarry, VP, Corp. Controller & Principal Accounting Officer (Age 54)
  • Ms. Megan C. Timmins, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. James A. McCarthy, Sr. VP of Bus. & Corp. Devel.
  • Mr. Timothy T. Chole, Sr. VP of Sales & Marketing
  • Dr. Marc L. Hoffman, Chief Medical Officer (Age 61)
  • Mr. David J. Kull, Sec. (Age 54)
  • Mr. Jason Finkelstein, Investor Relations Representative

What is Robert L. Chioini's approval rating as Rockwell Medical's CEO?

6 employees have rated Rockwell Medical CEO Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among Rockwell Medical's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

What is Rockwell Medical's stock symbol?

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Who are Rockwell Medical's major shareholders?

Rockwell Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Richmond Brothers Inc. (7.34%), Perkins Capital Management Inc. (4.39%), Vanguard Group Inc. (3.14%), Verdence Capital Advisors LLC (0.57%), Renaissance Technologies LLC (0.30%) and Northern Trust Corp (0.17%). Company insiders that own Rockwell Medical stock include Angus W Smith, David S Richmond, Russell H Ellison and Stuart M Paul.
View institutional ownership trends for Rockwell Medical
.

Which major investors are selling Rockwell Medical stock?

RMTI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Richmond Brothers Inc., and Northern Trust Corp.
View insider buying and selling activity for Rockwell Medical
or view top insider-selling stocks.

Which major investors are buying Rockwell Medical stock?

RMTI stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Verdence Capital Advisors LLC, Renaissance Technologies LLC, and Group One Trading L.P..
View insider buying and selling activity for Rockwell Medical
or or view top insider-buying stocks.

How do I buy shares of Rockwell Medical?

Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rockwell Medical's stock price today?

One share of RMTI stock can currently be purchased for approximately $1.49.

How much money does Rockwell Medical make?

Rockwell Medical (NASDAQ:RMTI) has a market capitalization of $12.73 million and generates $61.93 million in revenue each year.

How many employees does Rockwell Medical have?

Rockwell Medical employs 300 workers across the globe.

When was Rockwell Medical founded?

Rockwell Medical was founded in 1995.

How can I contact Rockwell Medical?

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The official website for Rockwell Medical is www.rockwellmed.com. The company can be reached via phone at (248) 960-9009, via email at [email protected], or via fax at 248-960-9119.

This page (NASDAQ:RMTI) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.